Trial reportJournal of ovarian research2019
Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.
Trial report in Journal of ovarian research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03608813 (Effects of a Combined Treatment With Myo-inositol, D-chiro-inositol and Glucomannan in Women With PCOS), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of a Combined Treatment With Myo-inositol, D-chiro-inositol and Glucomannan in Women With PCOS
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Paediatric obesity: a systematic review and pathway mapping of metabolic alterations underlying early disease processes.Molecular medicine (Cambridge, Mass.) · 2021Pooled it
- The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial.Frontiers in endocrinology · 2020Trial
- Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome.International journal of molecular sciences · 2023Review
- Placental Metabolomics of Fetal Growth Restriction.Metabolites · 2023Article
- Choline supplementation regulates gut microbiome diversity, gut epithelial activity, and the cytokine gene expression in gilts.Frontiers in nutrition · 2023Article
- Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol.Bioinformation · 2022Article
- Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure.Bioengineered · 2021Article
- Article
- Ascorbic Acid and Alpha-Tocopherol Contribute to the Therapy of Polycystic Ovarian Syndrome in Mouse Models.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- D-Chiro-Inositol Regulates Insulin Signaling in Human Adipocytes.Frontiers in endocrinology · 2021Article
- Inositols in PCOS.Molecules (Basel, Switzerland) · 2020Review
- Altered lung tissue lipidomic profile in caspase-4 positive non-small cell lung cancer (NSCLC) patients.Oncotarget · 2020Article
- Metabolomics in Central Sensitivity Syndromes.Metabolites · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundPolycystic ovarian syndrome (PCOS) is a highly variable syndrome and one of the most common female endocrine disorders. Although the association inositols-glucomannan may represent a good therapeutic strategy in the treatment of PCOS women with insulin resistance, the effect of inositols on the metabolomic profile of these women has not been described yet.
resultsFifteen PCOS-patients and 15 controls were enrolled. Patients were treated with myo-inositol (1.75 g/day), D-chiro-inositol (0.25 g/day) and glucomannan (4 g/day) for 3 months. Blood concentrations of glucose, insulin, triglycerides and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and for cases before and after treatment. PCOS-patients had higher BMI compared with Controls, BMI decreased significantly after 3 months of treatment although it remained significantly higher compared to controls. 3-methyl-1-hydroxybutyl-thiamine-diphosphate, valine, phenylalanine, ketoisocapric, linoleic, lactic, glyceric, citric and palmitic acid, glucose, glutamine, creatinine, arginine, choline and tocopherol emerged as the most relevant metabolites for distinguishing cases from controls.
conclusionOur pilot study has identified a complex network of serum molecules that appear to be correlated with PCOS, and with a combined treatment with inositols and glucomannan.
trial registrationClinicalTial.gov, NCT03608813 . Registered 1st August 2018 - Retrospectively registered, .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.